Literature DB >> 10455252

Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw.

N Vergnolle1, M D Hollenberg, K A Sharkey, J L Wallace.   

Abstract

In the present study, we have observed the development of an inflammatory reaction in the rat hindpaw, following the injection of specific agonists of PAR2 (two PAR2 activating peptides). This inflammation was characterized by oedema and granulocyte infiltration. Two selective PAR2 activating peptides, SLGRL-NH2 and trans-cinnamoyl-LIGRLO-NH2 induced significant oedema in the rat hindpaw from 1-6 h following subplantar injection. Six hours after the PAR2-activating peptide injection, the paw tissues showed a complete disruption of tissue architecture along with an inflammatory cell infiltrate. In the inflamed paw, PAR2-immunoreactivity was expressed on endothelial cells as well as on the infiltrating inflammatory cells. The oedema induced by the injection of the two PAR2 activating peptides was slightly reduced in rats pre-treated with compound 48/80, but was not modified by pre-treatment of rats with cromolyn, a mast cell stabilizer. Pre-treatment of rats with a cyclo-oxygenase inhibitor (indomethacin) or a nitric oxide synthase inhibitor (L-N(omega)-nitro-L-arginine methyl ester) had no effect on the oedema induced by the PAR2-activating peptides. These results demonstrate that the administration of PAR2-activating peptides into the rat paw induced an acute inflammatory response characterized by a persistent oedema (at least 6 h) and granulocyte infiltration. The PAR2-induced inflammatory response occurred through a mechanism largely independent of mast cell activation, and of the production of prostanoids and nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455252      PMCID: PMC1566112          DOI: 10.1038/sj.bjp.0702634

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Vascular effects of proteinase-activated receptor 2 agonist peptide.

Authors:  K Emilsson; C Wahlestedt; M K Sun; S Nystedt; C Owman; J Sundelin
Journal:  J Vasc Res       Date:  1997 Jul-Aug       Impact factor: 1.934

2.  Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides.

Authors:  M D Hollenberg; M Saifeddine; B al-Ani; A Kawabata
Journal:  Can J Physiol Pharmacol       Date:  1997-07       Impact factor: 2.273

3.  Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2.

Authors:  C U Corvera; O Déry; K McConalogue; S K Böhm; L M Khitin; G H Caughey; D G Payan; N W Bunnett
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2.

Authors:  W Kong; K McConalogue; L M Khitin; M D Hollenberg; D G Payan; S K Böhm; N W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

5.  Identification of potential activators of proteinase-activated receptor-2.

Authors:  M T Fox; P Harriott; B Walker; S R Stone
Journal:  FEBS Lett       Date:  1997-11-17       Impact factor: 4.124

6.  Interactions of mast cell tryptase with thrombin receptors and PAR-2.

Authors:  M Molino; E S Barnathan; R Numerof; J Clark; M Dreyer; A Cumashi; J A Hoxie; N Schechter; M Woolkalis; L F Brass
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

7.  Protease-activated receptor 3 is a second thrombin receptor in humans.

Authors:  H Ishihara; A J Connolly; D Zeng; M L Kahn; Y W Zheng; C Timmons; T Tram; S R Coughlin
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

8.  Cloning and characterization of human protease-activated receptor 4.

Authors:  W F Xu; H Andersen; T E Whitmore; S R Presnell; D P Yee; A Ching; T Gilbert; E W Davie; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

9.  Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport.

Authors:  N Vergnolle; W K Macnaughton; B Al-Ani; M Saifeddine; J L Wallace; M D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Proteinase-activated receptor-2: expression by human neutrophils.

Authors:  G L Howells; M G Macey; C Chinni; L Hou; M T Fox; P Harriott; S R Stone
Journal:  J Cell Sci       Date:  1997-04       Impact factor: 5.285

View more
  66 in total

1.  Proteinase-activated receptor 2 activation modulates guinea-pig mesenteric lymphatic vessel pacemaker potential and contractile activity.

Authors:  Alice K Chan; Nathalie Vergnolle; Morley D Hollenberg; Pierre-Yves von der Weid
Journal:  J Physiol       Date:  2004-08-26       Impact factor: 5.182

Review 2.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 3.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

4.  Protease-activated receptor-2 protects against pancreatitis by stimulating exocrine secretion.

Authors:  Vijay P Singh; Lakshmi Bhagat; Sarah Navina; Rifat Sharif; Rajinder K Dawra; Ashok K Saluja
Journal:  Gut       Date:  2006-11-17       Impact factor: 23.059

5.  Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

Authors:  Thomas Gobbetti; Nicolas Cenac; Jean-Paul Motta; Corinne Rolland; Laurence Martin; Patricia Andrade-Gordon; Martin Steinhoff; Elisabetta Barocelli; Nathalie Vergnolle
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

6.  Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain.

Authors:  Yi Dai; Shenglan Wang; Makoto Tominaga; Satoshi Yamamoto; Tetsuo Fukuoka; Tomohiro Higashi; Kimiko Kobayashi; Koichi Obata; Hiroki Yamanaka; Koichi Noguchi
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

7.  A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.

Authors:  Toshiaki Sendo; Yoshinori Itoh; Takeshi Goromaru; Tomoko Sumimura; Mami Saito; Keisei Aki; Takahisa Yano; Ryozo Oishi
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  Glycosylation and the activation of proteinase-activated receptor 2 (PAR(2)) by human mast cell tryptase.

Authors:  S J Compton; B Renaux; S J Wijesuriya; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

9.  Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents.

Authors:  Steeve Houle; Martin D Papez; Mara Ferazzini; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

10.  Protease activated receptors in cardiovascular function and disease.

Authors:  Junor A Barnes; Shamjeet Singh; Aldrin V Gomes
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.